{"schema_version":"secwatch.filing_event.v1","accession":"0001420720-26-000028","form_type":"8-K","ticker":"IBIO","cik":"0001420720","company_name":"iBio, Inc.","filed_at":"2026-09-14T20:16:45+00:00","discovered_at":"2026-09-14T20:18:10.708094+00:00","generated_at":"2026-09-14T20:18:33.408589+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"confidence":"low","headline":"iBio updates corporate presentation focused on antibodies for obesity and cardiometabolic diseases","bullets":["Corporate presentation dated September 2026 filed as Exhibit 99.1; highlights breakthrough antibodies for obesity and cardiometabolic diseases.","No specific pipeline milestones, financial figures, or clinical data disclosed in the filing excerpt.","Filing notes forward-looking statements and risks including regulatory approvals, financing, and Nasdaq listing maintenance.","Presentation updated for meetings with investors, analysts, and others; no other material events reported."],"urls":{"canonical":"https://secwatch.observer/filing/0001420720-26-000028","json":"https://secwatch.observer/filing/0001420720-26-000028.json","markdown":"https://secwatch.observer/filing/0001420720-26-000028.md","text":"https://secwatch.observer/filing/0001420720-26-000028.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1420720/000142072026000028/0001420720-26-000028-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1420720/000142072026000028/ibio-20260914x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-14T20:18:33.408589+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}